“I was part of the team responsible for bringing the first PARP inhibitor to patients with ovarian cancer. It is now licensed for the treatment of breast, prostate and pancreatic cancers and has made a real difference to these patients' lives. I think this must be the best incentive for working in the pharmaceutical industry.”